NEW ANTITHROMBOTIC AGENT Russian patent published in 2015 - IPC C07D401/04 C07D401/14 C07D403/14 C07D413/14 C07D417/14 C07D471/04 C07D487/04 A61K31/4439 A61K31/444 A61K31/4545 A61K31/496 A61K31/497 A61K31/501 A61K31/506 A61K31/5377 A61P7/02 A61P9/00 A61P9/08 A61P9/10 

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of formula or their pharmaceutically acceptable salts, wherein X^a represents N or CH; R^1e represents C_1-6-alkyl optionally substituted by aryl specified in phenyl, naphthyl, fenanthryl and anthryl, or by halogen; C_1-6-alkoxy optionally substituted by aryl specified in phenyl, naphthyl, fenanthryl and anthryl, by halogen or C_3-8-cycloalkyl; C_2-6-alkenyl; C_3-8-cycloalkyl; or halogen; R^1f represents hydrogen, C_1-6-alkyl, C_1-6-alkoxy, hydroxyl, cyano or halogen; R²¹ represents 5-10-merous heteroaryl, which has 1-3 heteroatoms specified in nitrogen, oxygen or sulphur, and which can be substituted by identical or different 1-3 groups specified in the patent claim; R³¹ represents 6-merous heteroaryl, which has 1 or 2 nitrogen atoms, and which can be substituted by identical or different 1-3 groups specified in the patent claim. The invention also refers to an antithrombotic agent and a medicinal product containing the compounds of formula IIa as an active ingredient, to a method for preventing thrombocyte aggregation, and a method for preventing or treating ischemic stroke, acute coronary syndrome, microvascular dysfunction, peripheral arterial disease, arteriosclerosis obliterans, ischemic heart disease, thrombotic microangiopathy, or unstable or stable angina.

EFFECT: compounds of formula IIa exhibiting the inhibitory activity on thrombocyte aggregation.

18 cl, 34 tbl, 192 ex